Purple Biotech Regains Nasdaq Compliance, Mitigating Delisting Risk
PPBT sits 17% above its 52-week low of $3.7.
Summary
Purple Biotech announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on The Nasdaq Capital Market.
Key Events · Corporate Governance and Compliance · PPBT
-
Regains Nasdaq Compliance
Purple Biotech received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
-
Achieved Minimum Bid Price
Compliance was achieved by maintaining a closing bid price of $1.00 or more for at least 10 consecutive business days, concluding on March 13, 2026.
Analysis · PPBT · Life Sciences
This filing announces that Purple Biotech has successfully regained compliance with Nasdaq's minimum bid price requirement, removing the immediate threat of delisting. For a micro-cap company, maintaining its listing on a major exchange like Nasdaq is critical for investor visibility, liquidity, and access to capital markets. This positive development provides stability for the company's trading status, following a recent negative announcement regarding a significant impairment loss.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PPBT was trading at $4.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $3.70 to $30.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.